Kite Pharma Raises $15M

Los Angeles-based Kite Pharma, a biopharmaceuticals firm developing treatments for cancer, said this morning that it has raised $15M in an initial round of funding. The funding was led by TPG Capital. As part of the funding, David Bonderman of TPG Capital joins the firm's board of directors. Kite Pharma said it is developing active immunotherapies for cancer. The investment ronud came with the assistance of Riverbank Capital Securities Inc., which acted as a placement agent in the financing. Kite Pharma is headed by Aya Jakobovits, Ph.D. More information »